Back to top

Image: Bigstock

Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know

Read MoreHide Full Article

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Jasper Therapeutics, Inc. (JSPR - Free Report) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Jasper Therapeutics, Inc. Currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?

Let's discuss some of the components of the Momentum Style Score for JSPR that show why this company shows promise as a solid momentum pick.

A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.

For JSPR, shares are up 24.77% over the past week while the Zacks Medical - Biomedical and Genetics industry is down 1.5% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 53.26% compares favorably with the industry's 1.28% performance as well.

While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Shares of Jasper Therapeutics, Inc. Have increased 384.45% over the past quarter, and have gained 41% in the last year. In comparison, the S&P 500 has only moved 10.08% and 35.76%, respectively.

Investors should also pay attention to JSPR's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. JSPR is currently averaging 127,750 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with JSPR.

Over the past two months, 3 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost JSPR's consensus estimate, increasing from -$6.12 to -$5.20 in the past 60 days. Looking at the next fiscal year, 3 estimates have moved upwards while there have been no downward revisions in the same time period.

Bottom Line

Taking into account all of these elements, it should come as no surprise that JSPR is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Jasper Therapeutics, Inc. On your short list.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Jasper Therapeutics, Inc. (JSPR) - free report >>

Published in